Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 22 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ziltivekimab (Primary)
Indications Cardiovascular disorders; Inflammation
Focus Therapeutic Use
Acronyms RESCUE
Sponsors Corvidia Therapeutics; Novo Nordisk

Most Recent Events

01 Jan 2024 Status changed to discontinued, according to Results published in the Journal of the American Society of Nephrology.
01 Jan 2024 Results of exploratory analysis assessing the effect of ziltivekimab on Hb and iron homeostasis, published in the Journal of the American Society of Nephrology.
19 May 2021 Results assessing effect of ziltivekimab on the neutrophil-lymphocyte ratio, published in the Lancet Journal.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com